Abterra Bio awarded $1.8M NIH SBIR to extend antibody repertoire analysis software, REPTOR Next-generation sequencing is a valuable readout for antibody discovery campaigns, but current software does not address the real pain points of analysis. Abterra Biosciences...
Abterra Opens Its Doors To Celebrate New Location With Open House Celebrating milestones is an important part of our personal and professional journeys. We wanted to commemorate this exciting new chapter in Abterra’s story with the people who mean the most to...
Abterra Bio Has Moved To Sorrento Valley In 2009, Abterra Bio began as Digital Proteomics LLC, a spin-out of the University of California – San Diego. Founders Pavel Pevzner and Vineet Bafna, as well as Natalie Castellana, Stefano Bonissone, and Anand Patel have been...
PEGS Boston Summit 2021 Presentation Abstract: Next-generation sequencing of antibody repertoires has provided new insights into natural immune responses. The correlation between the B-cell receptor repertoire and the serological antibody repertoire has only been...
Abterra Bio Seattle Angel Conference Winner We’re excited to announce that Abterra Bio has been chosen as the Winner of the 19th Seattle Angel Conference and the Audience Favorite Award. This year, there were 81 start-up companies from all over the US that had...
Digital Proteomics is Abterra Biosciences We’re excited to announce that Digital Proteomics is now Abterra Biosciences. Our vision for the business has evolved and it’s time to realign our name with our capabilities; we have developed core technologies...
